The Educational Programmes on this page cover the following items:
The SHARE Communication Framework for mCRPC
SHARE provides a simple 5-step approach aimed at improving outcomes through engaging patients with metastatic castration resistant prostate cancer (mCRPC) in their own treatment decision. Educational videos will help you quickly apply the SHARE Communication Framework and move towards even better patient conversations.
Advanced PET Imaging in Prostate Cancer
Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer
Adjuvant Therapy in mRCC
This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC
GU CONNECT Update from…
GU CONNECT Update from ESMO 2019
GU CONNECT has summarised highlights of the recent ESMO 2019 meeting for you
GU CONNECT Update from ASCO 2019
GU CONNECT has summarised the highlights from ASCO 2019 for you
Update from ASCO GU 2019
GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.
GU CONNECT Update from ESMO 2018
GU CONNECT has summarised the highlights from ESMO 2018 for you.
ASCO GU 2018
Update from San Francisco 2018
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
A CONNECT Update from Madrid
GU CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.
ASCO GU 2017
GU CONNECT update from Orlando
GU CONNECT has summarised the highlights of the recent congress of the American Society of Clinical Oncology GU (ASCO GU) 2017 in Orlando, USA for you
Your clinical questions answered
Please submit your clinical topic for the next GU CONNECT newsletter here.
Treatment sequencing for mCRPC patients within the changing landscape of mHSPC: An engaging discussion during ESMO 2019
Dr. Cora Sternberg led an interesting Experts Knowledge Share on the topic of ‘Treatment sequencing for mCRPC patients within the changing landscape of mHSPC’ with Dr. Gert Attard and Dr. Alicia Morgans presenting two alternative treatment approaches.
New therapies for metastatic hormone sensitive prostate cancer
As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.
Treating Oligometastatic Prostate Cancer
Assoc. Prof. Tanya B. Dorff looks into the use of imaging along with the treatment of oligometastatic prostate cancer
Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)
Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.
An update on the treatment of patients with mCRPC with RA-223 plus AAP
Dr. Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC
Advances in metastatic hormone-sensitive prostate cancer
Associate Professor Alicia Morgans provides her thoughts on the recent advances in metastatic hormone-sensitive prostate cancer
How to use combination, sequential and immuno-oncology therapies in mCRPC?
Professor of Medicine Evan Yu and Associate Professor Tanya Dorff provide their thoughts and views on combination, sequential and immuno-oncology therapies in mCRPC (Metastatic Castration-Resistant Prostate Cancer)
An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients
Dr. Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.
Relevant papers discussed